{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+bolus+%26+placebo+infusion", "query": { "intervention": "Placebo bolus & placebo infusion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 195, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+bolus+%26+placebo+infusion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T19:10:27.059Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00130169", "title": "A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer, Malignant Tumors" ], "interventions": [ { "name": "E7974", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-01", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2015-07-01", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 2, "location_summary": "Las Vegas, Nevada • Stony Brook, New York", "locations": [ { "city": "Las Vegas", "state": "Nevada" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00130169" }, { "nct_id": "NCT01076764", "title": "Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Otamixaban", "type": "DRUG" }, { "name": "Placebo (for Otamixaban)", "type": "DRUG" }, { "name": "UFH", "type": "DRUG" }, { "name": "Placebo (for UFH)", "type": "DRUG" }, { "name": "Eptifibatide", "type": "DRUG" }, { "name": "Placebo (for Eptifibatide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13220, "start_date": "2010-04", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2016-05-04", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 107, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01076764" }, { "nct_id": "NCT02043587", "title": "Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphocytic Leukemia", "Adult Lymphoblastic Lymphoma" ], "interventions": [ { "name": "DNR", "type": "DRUG" }, { "name": "VCR", "type": "DRUG" }, { "name": "PEG-asp", "type": "DRUG" }, { "name": "CTX", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Liposomal AraC", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "LCV", "type": "DRUG" }, { "name": "AraC", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 31, "start_date": "2014-01", "completion_date": "2022-04-14", "has_results": false, "last_update_posted_date": "2022-05-02", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043587" }, { "nct_id": "NCT01950520", "title": "Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Propranolol", "type": "DRUG" }, { "name": "Pindolol", "type": "DRUG" }, { "name": "Dantrolene", "type": "DRUG" }, { "name": "Magnesium Sulfate", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Qsymia", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" }, { "name": "Phentermine", "type": "BEHAVIORAL" }, { "name": "Naltrexone", "type": "DRUG" }, { "name": "Mirabegron 50mg", "type": "DRUG" }, { "name": "Mirabegron 200mg", "type": "DRUG" }, { "name": "Placebo Cohort 1", "type": "DRUG" }, { "name": "Placebo Cohort 2", "type": "DRUG" }, { "name": "Placebo for Mirabegron", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "MALE", "summary": "18 Years to 35 Years · Male only" }, "enrollment_count": 47, "start_date": "2014-02-07", "completion_date": "2024-06-11", "has_results": true, "last_update_posted_date": "2024-10-16", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01950520" }, { "nct_id": "NCT03397966", "title": "Metabolic Effects of Natriuretic Peptide Hormones", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity", "Cardiovascular Physiological Phenomena", "Metabolism" ], "interventions": [ { "name": "recombinant human BNP(1-32)", "type": "DRUG" }, { "name": "placebo (control, normal saline)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 5, "start_date": "2018-07-01", "completion_date": "2019-05-01", "has_results": true, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03397966" }, { "nct_id": "NCT01824082", "title": "Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Phantom Limb Pain" ], "interventions": [ { "name": "Perineural infusion [continuous peripheral nerve block(s)]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2013-12-01", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 4, "location_summary": "Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01824082" }, { "nct_id": "NCT00305162", "title": "A Clinical Trial to Demonstrate the Efficacy of Cangrelor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myocardial Infarction (MI)", "Acute Coronary Syndromes (ACS)" ], "interventions": [ { "name": "Cangrelor (P2Y12 inhibitor)", "type": "DRUG" }, { "name": "clopidogrel (oral P2Y12 inhibitor)", "type": "DRUG" }, { "name": "Placebo bolus & placebo infusion", "type": "DRUG" }, { "name": "Placebo capsules - end of infusion", "type": "DRUG" }, { "name": "Placebo capsules - as soon as possible after randomization", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8882, "start_date": "2006-04", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2014-05-08", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00305162" }, { "nct_id": "NCT00559338", "title": "Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure, Congestive", "Cardiomyopathy" ], "interventions": [ { "name": "recombinant B-type, natriuretic peptide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2003-12", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2007-11-16", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559338" }, { "nct_id": "NCT01981863", "title": "Fibrinolysis Before Cardiopulmonary Bypass?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pathologic Fibrinolysis" ], "interventions": [ { "name": "Epsilonaminocaproic acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-07", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01981863" }, { "nct_id": "NCT02320669", "title": "Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Heart Defects" ], "interventions": [ { "name": "Triostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "5 Months", "sex": "ALL", "summary": "Up to 5 Months" }, "enrollment_count": 220, "start_date": "2014-11", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-10-07T19:10:27.059Z", "location_count": 3, "location_summary": "Los Angeles, California • Palo Alto, California • Seattle, Washington", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320669" } ] }